Drug Profile
Imatinib - Pharm-Sintez
Alternative Names: ImatibLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Pharm-Sintez
- Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Hypereosinophilic syndrome; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma; Systemic mastocytosis
Most Recent Events
- 12 Feb 2019 Chemical structure information added